Details for Patent: 8,217,083
✉ Email this page to a colleague
Which drugs does patent 8,217,083 protect, and when does it expire?
Patent 8,217,083 protects CANASA and is included in one NDA.
This patent has thirteen patent family members in twelve countries.
Summary for Patent: 8,217,083
Title: | Mesalamine suppository |
Abstract: | The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 850 to about 1150 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 2250 to about 2700 mg. Another embodiment of the invention is a mesalamine rectal suppository comprising from about 400 to about 600 mg mesalamine and one or more pharmaceutically acceptable excipients, wherein the total weight of the suppository ranges from about 870 to about 1715 mg. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5.degree. C. Methods of preparing and methods of treatment with mesalamine suppositories are also provided. The invention further provides a method of determining a dissolution parameter (such as dissolution rate) of a mesalamine rectal suppository, such as a 1 g mesalamine suppository, by measuring its dissolution with USP Apparatus #2 at 40.degree. C. and a paddle rotation speed of 125 rpm in 0.2 M phosphate buffer at a pH of 7.5. |
Inventor(s): | Gauthier; Carl (Quebec, CA), Dumoulin; Yves (Quebec, CA), Powell; David (Loudon, TN) |
Assignee: | Aptalis Pharma Canada Inc. (Mont-Saint-Hilaire, Quebec, CA) |
Application Number: | 12/476,185 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,217,083 |
Patent Claim Types: see list of patent claims | Formulation; Dosage form; Use; |
Drugs Protected by US Patent 8,217,083
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | CANASA | mesalamine | SUPPOSITORY;RECTAL | 021252-002 | Nov 5, 2004 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,217,083
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2010339837 | ⤷ Try a Trial | |||
Canada | 2690450 | ⤷ Try a Trial | |||
Canada | 2784772 | ⤷ Try a Trial | |||
Chile | 2012001636 | ⤷ Try a Trial | |||
China | 102970971 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |